A Look at Rising Inventory Levels for Top Cannabis Players

Top cannabis players have lost 75% in market value over the last year. Here’s why investors can expect weakness to continue in the short-term.

edit Jars of marijuana

Image source: Getty Images

In the last week, we saw several cannabis players announce their quarterly results that disappointed investors. Cannabis manufacturers have been impacted by competition and rampant cannibalization of product sales from the illegal market.

While Canada legalized marijuana for recreational use last October, the country’s illegal market still accounts for 40% of total adult-use sales due to lower prices.

The slow rollout of retail stores has also hampered sales, resulting in lower than expected revenue growth for cannabis companies.

Companies were banking on the Ontario province to drive sales, but according to one Cannabis benchmark report, the province has about 24 operating stores to date. The increasing demand-supply gap has resulted in high inventory levels for cannabis manufacturers.

Aurora, Canopy, and Cronos witness considerable growth in inventory value

Aurora Cannabis (TSX:ACB)(NYSE:ACB) announced its fiscal first quarter of 2020 (year ending in June) results last week, reporting net revenue of $75.24 million, a fall of 19% sequentially.

Comparatively, the company’s inventory value rose 33.5% from $113.6 million in the first quarter of fiscal 2019 to $151.76 million in the first quarter of 2020.

ACB’s inventory levels account for 34% of the estimated 2020 sales.

Canopy Growth (TSX:WEED)(NYSE:CGC) also announced its fiscal second quarter of 2020 (year ending in March) results and reported net revenue of $76.61 million, a fall of 15.3% sequentially.

Comparatively, the company’s inventory value rose 17.3% from $393 million in the second quarter of fiscal 2019 to $462 million in the second quarter of 2020. Canopy’s inventory levels account for 77% of the estimated 2020 sales.

Cronos Group (TSX:CRON)(NASDAQ:CRON) announced its third quarter 2019 results and reported a net revenue of $12.7 million, a rise of 24% sequentially. Comparatively, the company’s inventory value rose 27% from $41.66 million in the third quarter of fiscal 2018 to $52.86 million in the third quarter of 2019. Cronos’ inventory levels account for 137% of estimated 2019 sales.

These high inventory levels strongly put the focus on tepid demand for marijuana producers. Cannabis Benchmarks estimated top players such as Aurora and Canopy Growth to sell just 30% of the total harvest in the September quarter.

Although most manufacturers are heavily spending on increasing production capacity, they’re finding it difficult to generate demand in a highly regulated market. Should high inventory levels persist, investors can expect million-dollar write-downs due to degradation of the inventory.

In fact, Canopy Growth had to write-down $15.9 million of inventory in the September quarter — almost 20% of its quarterly sales. Although the capital expenditure investments are helping manufacturers reduce production costs and increase gross margins, it is offset by lower product demand, which in turn hits the bottom line hard.

Aurora, Canopy, and Cronos are have burnt significant investor wealth

The structural issues impacting cannabis companies has resulted in severe wealth erosion for investors. Shares of Aurora Cannabis are trading at $3.24 at writing, which is 76% below record highs.

Similarly, Canopy Growth stock is trading at $19.45 which is 75% below record highs while Cronos stock is trading at $8.2, which is 75% below record highs.

The near-term concerns are expected to weigh on pot producers over the next few months, which means increased volatility for investors as we head into 2020.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »